BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Nirmal Bang initiates Strides Shahun with buy
Shasun Pharmaceutical's merger with Strides Arcolab, which completed in Q3 of last fiscal, will significantly strengthen combined entity Strides Shasun's business model and will bring in a great deal of synergy. Strides Shasun represents a right mix of robust growth, improved return ratios and a strong balance sheet. We value the company at 18 times FY18 estimated EPS of Rs 68.6.